Is There Still a Role for Endocrine Therapy Alone in HR+/HER2 – Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies
Conclusion: These data suggest that HD-FUL should still continue to play a significant role as first-line therapy in HR+ ABC patients.Breast Care (Source: Breast Care)
Source: Breast Care - April 18, 2019 Category: Cancer & Oncology Source Type: research

St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment
This year, the St. Gallen Consensus Conference on early breast cancer treatment standards took place for the third time in Vienna, Austria, which is where the next conference will also take place (next date: March 17 –20, 2021!). Once again, more than 3,000 participants from over 100 countries came together, and, overall, the 2019 St. Gallen/Vienna conference was a great success. After 3 days of reviews conducted by a global faculty concerning the most important evidence published in the last 2 years, the Cons ensus votes’ challenge was to define the impact on routine everyday practice. This year, the conferenc...
Source: Breast Care - April 15, 2019 Category: Cancer & Oncology Source Type: research

Luminal Metastatic Breast Cancer
Breast Care (Source: Breast Care)
Source: Breast Care - April 15, 2019 Category: Cancer & Oncology Source Type: research

Prevention and Management of Chemotherapy-Induced Polyneuropathy
Chemotherapy-induced peripheral neurotoxicity (CIPN) is a severe and common side effect caused by a variety of antineoplastic agents. Approximately 30 –40% of patients treated with agents such as taxanes, vinca alkaloids, or platinum derivatives will develop CIPN. CIPN presents predominantly as a sensory axonal neuro(no)pathy with occasional motor and autonomic dysfunction exhibiting considerable variability of clinical symptoms ranging from mil d tingling sensation to severe neuropathic pain. Typical symptoms include numbness (“minus symptom”), weakness, and abnormal gait as well as paresthesia and pain ...
Source: Breast Care - April 15, 2019 Category: Cancer & Oncology Source Type: research

Management of Adverse Events Due to Cyclin-Dependent Kinase 4/6 Inhibitors
Cyclin-dependent kinase (CDK) 4/6 inhibitors have become standard of care in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer. They have been shown to double the efficacy of endocrine-based treatment. Three oral agents are available to date: palbociclib, ribociclib, and abemaciclib. The aim of this article is to give a short overview of the existing efficacy data, to summarize the recommended clinical monitoring procedures for patients under CDK4/6 inhibitors, and to shed light on the clinical management of the most common treatment-emergent adverse even...
Source: Breast Care - March 31, 2019 Category: Cancer & Oncology Source Type: research

Supportive Care – Different Agents and Strategies in the Combat against Toxicities in Anticancer Therapy
Breast Care (Source: Breast Care)
Source: Breast Care - March 31, 2019 Category: Cancer & Oncology Source Type: research

Hematopoietic Growth Factors in the Management of Anemia and Febrile Neutropenia
Chemotherapy-induced anemia (CIA) in cancer patients correlates with poor performance status and decreased quality of life. Currently recommended causal therapies are erythropoiesis-stimulating agents (epoetins), iron substitution, or a combination of both. Guidelines recommend considering red blood cell (RBC) transfusions for symptomatic anemia at a hemoglobin (Hb) level of (Source: Breast Care)
Source: Breast Care - March 14, 2019 Category: Cancer & Oncology Source Type: research

Location and Frequency of Residual Breast Tissue after Mastectomy
Conclusion: Mastectomy has a high probability of residual breast tissue being left behind. Physicians should be aware of this and act accordingly when planning surgical or follow-up treatment.Breast Care (Source: Breast Care)
Source: Breast Care - March 14, 2019 Category: Cancer & Oncology Source Type: research

What Does the Pipeline Promise about Upcoming Biosimilar Antibodies in Oncology?
The introduction of biosimilars of biological agents for which the patents and exclusivity periods have expired is an attractive way of reducing healthcare spending through price competition with the reference product. In oncology, biosimilars of growth factors for supportive therapy were the pioneers; now, monoclonal antibody biosimilars are conquering the market. In Europe, this is currently limited to biosimilars of the monoclonal antibodies trastuzumab and rituximab. However, the pipeline is full and several monoclonal antibody biosimilars in oncology are now in late-stage development. We are expecting not only more bi...
Source: Breast Care - March 7, 2019 Category: Cancer & Oncology Source Type: research

Meetings and Conferences
Breast Care 2019;14:67-68 (Source: Breast Care)
Source: Breast Care - March 7, 2019 Category: Cancer & Oncology Source Type: research

Title Page / Table of Contents
Breast Care 2019;14:I-VI (Source: Breast Care)
Source: Breast Care - March 7, 2019 Category: Cancer & Oncology Source Type: research

PharmaNews
Breast Care 2019;14:64-65 (Source: Breast Care)
Source: Breast Care - March 7, 2019 Category: Cancer & Oncology Source Type: research

PharmaNews
Breast Care 2019;14:63 (Source: Breast Care)
Source: Breast Care - March 7, 2019 Category: Cancer & Oncology Source Type: research

Comparison of Subpectoral versus Prepectoral Immediate Implant Reconstruction after Skin- and Nipple-Sparing Mastectomy in Breast Cancer Patients: A Retrospective Hospital-Based Cohort Study
Introduction: Implant-based immediate breast reconstruction (IBR) is a common surgical procedure in breast cancer patients. Comparative analysis concerning the placement of implants is still lacking. Hence, we aimed to analyze pre- versus subpectoral IBR in breast cancer patients.Patients: A single-center experience with implant-based IBR following skin/nipple-sparing mastectomy was evaluated. Patient demographics, incidence of major complications, and quality of life assessed with BREAST-Q were compared between the pre- and subpectoral cohort.Results: A total of 63 patients were included in this analysis of whom 29 underw...
Source: Breast Care - February 25, 2019 Category: Cancer & Oncology Source Type: research

Patient-Reported Satisfaction after Prophylactic Operations of the Breast
Conclusions: Prophylactic mastectomy is a procedure with risk for long-term complications in some cases. Our results confirm high satisfaction with the decision and improved quality of life.Breast Care (Source: Breast Care)
Source: Breast Care - February 14, 2019 Category: Cancer & Oncology Source Type: research

Long-Term Side Effects of Adjuvant Therapy in Primary Breast Cancer Patients: Results of a Web-Based Survey
Conclusion: Estimating the burden of chronic toxicities should contribute to enhance rational decision-making on treatments including chemotherapy in patients with low versus high risk of recurrence.Breast Care (Source: Breast Care)
Source: Breast Care - February 14, 2019 Category: Cancer & Oncology Source Type: research

Prophylaxis and Management of Skin Toxicities
Skin toxicity is a common problem not only when treating breast cancer but in all cancer types. Visible on the surface, these side effects come not just with burdening symptoms but also with stigmatization. With increasing diversity in therapeutic options, dermatologic side effects are also becoming increasingly complex and more challenging for the clinician. We reviewed the most common dermatologic side effects of current anticancer therapy, including toxicity induced by chemotherapy, targeted therapy, and immunotherapy. In particular, we focus on xerosis and pruritus, (acneiform) exanthema, hand-foot syndrome, nail toxic...
Source: Breast Care - February 14, 2019 Category: Cancer & Oncology Source Type: research

News from the San Antonio Breast Cancer Symposium 2018
Breast Care (Source: Breast Care)
Source: Breast Care - February 12, 2019 Category: Cancer & Oncology Source Type: research

What Does the Pipeline Promise about Upcoming Biosimilar Antibodies in Oncology
The introduction of biosimilars of biological agents for which the patents and exclusivity periods have expired is an attractive way of reducing healthcare spending through price competition with the reference product. In oncology, biosimilars of growth factors for supportive therapy were the pioneers; now, monoclonal antibody biosimilars are conquering the market. In Europe, this is currently limited to biosimilars of the monoclonal antibodies trastuzumab and rituximab. However, the pipeline is full and several monoclonal antibody biosimilars in oncology are now in late-stage development. We are expecting not only more bi...
Source: Breast Care - February 12, 2019 Category: Cancer & Oncology Source Type: research

ACT-FASTER, a Prospective Cohort Study Exploring Treatment Patterns with Fulvestrant and Exemestane in Postmenopausal Patients with Advanced Hormone Receptor-Positive Breast Cancer under Real-Life Conditions in Germany
Conclusion: Fulvestrant 500 mg was administered successfully to patients under daily practice conditions, and both medications were well tolerated. TTP was longest in patients treated with fulvestrant 500 mg 1 L compared with 2 L and 3 L in the palliative care setting.Breast Care (Source: Breast Care)
Source: Breast Care - February 8, 2019 Category: Cancer & Oncology Source Type: research

Emulsion of Olive Oil and Calcium Hydroxide for the Prevention of Radiation Dermatitis in Hypofractionation Post-Mastectomy Radiotherapy: A Randomized Controlled Trial
Conclusions: Addition of an emulsion of olive oil and calcium hydroxide for patients undergoing hypofractionation PMRT yielded superior preventive results over a general skin care regimen alone, in terms of delaying skin toxicity, reducing the severity of acute radiation dermatitis, and a better quality of life in the intervention group. However, a larger number of patients will be required to confirm this result.Breast Care (Source: Breast Care)
Source: Breast Care - February 4, 2019 Category: Cancer & Oncology Source Type: research

Effect of Trastuzumab among HER2-Positive Breast Cancer Patients that Achieved Pathologic Complete Response after Neoadjuvant Chemotherapy
Conclusion: The administration of trastuzumab should be considered standard treatment for HER2-positive patients who have achieved pCR after NACT alone.Breast Care (Source: Breast Care)
Source: Breast Care - February 4, 2019 Category: Cancer & Oncology Source Type: research

Promoter Methylation Status of the Retinoic Acid Receptor-Beta 2 Gene in Breast Cancer Patients: A Case Control Study and Systematic Review
Conclusion: We found a higher frequency ofRAR β2 gene methylation in the blood and cancer tissues of patients compared to the blood of controls and adjacent normal breast tissues. The survey of studies on various populations demonstrated a higherRAR β2 methylation frequency in breast cancer patients compared to normal individuals, and many reports suggest a significant association between hypermethylation of the gene and susceptibility to breast cancer.Breast Care (Source: Breast Care)
Source: Breast Care - January 31, 2019 Category: Cancer & Oncology Source Type: research

Recurrence of Primary Breast Angiosarcoma 7 Years after Mastectomy in a 17-Year-Old Woman: A Case Report
Conclusions: This is a rare case as the patient was below 18 years old and the follow-up was greater than 5 years. Taken together, long-term close follow-up is extremely important, regardless of how long after surgery and the status of the surgical margins.Breast Care (Source: Breast Care)
Source: Breast Care - January 31, 2019 Category: Cancer & Oncology Source Type: research

Diagnostic Accuracy of Breast Medical Tactile Examiners (MTEs): A Prospective Pilot Study
Conclusion: The predictive value for a suspicious breast lesion in CBEs performed by MTEs in patients without prior surgery was similar to that of physician-conducted CBEs. Including MTEs in the CBE procedure in breast units thus appears feasible and could be a way of utilizing their skills.Breast Care (Source: Breast Care)
Source: Breast Care - January 31, 2019 Category: Cancer & Oncology Source Type: research

Biosimilar Trastuzumab in Clinical Trials: Differences or Not
In the last decade, cancer therapies have increasingly taken the form of combination treatments in which biologic agents play a crucial role. In breast cancer, the treatment strategy is adjusted to intrinsic subtypes such as human epidermal growth factor receptor-2(HER2)-positive. With the introduction of trastuzumab, a monoclonal antibody against HER2, survival has significantly improved in early and metastatic breast cancer. Trastuzumab's patent has now expired and biosimilars are moving into the market. Several clinical trials have led to the approval of 5 different biosimilar trastuzumabs. Results proved similarity bet...
Source: Breast Care - January 31, 2019 Category: Cancer & Oncology Source Type: research

Position of Scientific Oncological Societies Towards Biosimilar Antibodies
First biosimilars of monoclonal antibodies have recently been approved in oncology. Biosimilars enable economic competition, alleviate the financial burden for insurances, and may facilitate access to these drugs in low-income countries. Biosimilars are not completely identical to the original drug. The approval of biosimilars is only partially based on results of randomized clinical studies. In the introduction phase of new biosimilars, this can lead to uncertainties for patients and physicians. Based on the current clinical data and experiences, biosimilars of monoclonal antibodies in oncology show no significant differe...
Source: Breast Care - January 14, 2019 Category: Cancer & Oncology Source Type: research

Approval by Authorities Does not Allow For Suboptimal Study Conduct but Offers New Academic Possibilities
Breast Care (Source: Breast Care)
Source: Breast Care - January 14, 2019 Category: Cancer & Oncology Source Type: research

Breastconsent 1
Breast Care 2018;13:I-IV (Source: Breast Care)
Source: Breast Care - December 20, 2018 Category: Cancer & Oncology Source Type: research

Acknowledgement to Reviewers
Breast Care 2018;13:399 (Source: Breast Care)
Source: Breast Care - December 19, 2018 Category: Cancer & Oncology Source Type: research

Contents Vol. 13, 2018
Breast Care 2018;13:473-476 (Source: Breast Care)
Source: Breast Care - December 19, 2018 Category: Cancer & Oncology Source Type: research

Meetings and Conferences
Breast Care 2018;13:469-472 (Source: Breast Care)
Source: Breast Care - December 19, 2018 Category: Cancer & Oncology Source Type: research

PharmaNews
Breast Care 2018;13:466-468 (Source: Breast Care)
Source: Breast Care - December 19, 2018 Category: Cancer & Oncology Source Type: research

PharmaForum
Breast Care 2018;13:465 (Source: Breast Care)
Source: Breast Care - December 19, 2018 Category: Cancer & Oncology Source Type: research

PharmaForum
Breast Care 2018;13:463-464 (Source: Breast Care)
Source: Breast Care - December 19, 2018 Category: Cancer & Oncology Source Type: research

Abstracts der Jahrestagung der Österreichischen Gesellschaft für Senologie (27.-29.09.18, Graz)
Breast Care 2018;13:456-462 (Source: Breast Care)
Source: Breast Care - December 19, 2018 Category: Cancer & Oncology Source Type: research

Benign Breast Tumours - Diagnosis and Management
With improvements in breast imaging, mammography, ultrasound and minimally invasive interventions, the detection of early breast cancer, non-invasive cancers, lesions of uncertain malignant potential, and benign lesions has increased. However, with the improved diagnostic capabilities comes a substantial risk of false-positive benign lesions and vice versa false-negative malignant lesions. A statement is provided on the manifestation, imaging, and diagnostic verification of isolated benign breast tumours that have a frequent manifestation, in addition to general therapy management recommendations. Histological evaluation o...
Source: Breast Care - December 18, 2018 Category: Cancer & Oncology Source Type: research

Editorial Board / Contents / Imprint
Breast Care 2018;13:393-398 (Source: Breast Care)
Source: Breast Care - December 18, 2018 Category: Cancer & Oncology Source Type: research

Benign Breast Diseases
Breast Care (Source: Breast Care)
Source: Breast Care - December 13, 2018 Category: Cancer & Oncology Source Type: research

Gynecomastia – Conservative and Surgical Management
Gynecomastia is defined as a unilateral or bilateral persistent benign mammary gland enlargement in men. Prevalence of asymptomatic gynecomastia is up to 65%. True gynecomastia must be distinguished from pseudogynecomastia. Typically, in true gynecomastia, a solid tissue mass is palpable below the nipple-areolar complex. Malignant changes such as male mammary carcinoma must always be ruled out. The causes of gynecomastia are diverse. An imbalance of female to male hormones triggers the onset of the disease. This imbalance can be caused by endogenous diseases like hyperthyroidism, chronic liver disease, primary or secondary...
Source: Breast Care - December 6, 2018 Category: Cancer & Oncology Source Type: research

Management of HER2-Positive Early Breast Cancer
Breast Care (Source: Breast Care)
Source: Breast Care - December 4, 2018 Category: Cancer & Oncology Source Type: research

Delayed Breast Cellulitis following Surgery for Breast Cancer: A Literature Review
Conclusion: The correct diagnostic approach is essential as it provides patients with reassurance, minimizes anxiety, and prevents unnecessary medical investigations, treatments, and costs.Breast Care (Source: Breast Care)
Source: Breast Care - November 30, 2018 Category: Cancer & Oncology Source Type: research

Effect of LigaSure ™, Monopolar Cautery, and Bipolar Cautery on Surgical Margins in Breast-Conserving Surgery
Conclusion: Thermal damage due to the excision method may cause false-negative and false-positive results in the surgical margin evaluation of lumpectomy specimens. More research is needed on the effects of different energy modalities on surgical margin evaluation in breast-conserving surgery.Breast Care (Source: Breast Care)
Source: Breast Care - November 30, 2018 Category: Cancer & Oncology Source Type: research

Granulomatous Mastitis: A Therapeutic and Diagnostic Challenge
Granulomatous mastitis (GM) is a rare benign inflammatory breast disease that affects mostly women of childbearing age with a history of breastfeeding. The etiopathogenesis is still unknown; however, inflammation as the result of a reaction to trauma, metabolic or hormonal processes, autoimmunity, and an infection withCorynebacterium kroppenstedtii have all been implicated. Clinical findings are pain, mass, hyperemia, and inflammation. Because the clinical presentation can mimic infectious mastitis or inflammatory carcinoma, the disease course is often protracted. The diagnosis is made by histopathology. Biopsies show a gr...
Source: Breast Care - November 22, 2018 Category: Cancer & Oncology Source Type: research

Efficacy of a CDK4/6 Inhibitor in a Patient with Breast Cancer and Liposarcoma: A Case Report and Review of the Literature
Conclusion: CDK4/6 inhibitors exhibit a high therapeutic potential, although reliable prognostic markers need to be identified.Breast Care (Source: Breast Care)
Source: Breast Care - November 13, 2018 Category: Cancer & Oncology Source Type: research

Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient
Conclusion: Within the overall goal to establish operating procedures for breast cancer immunotherapy, we propose to re-evaluate testing for deficient mismatch repair and to further intensify the search for biomarkers predictive for the success of immune checkpoint modulation including all tumor biologic subtypes of breast cancer.Breast Care (Source: Breast Care)
Source: Breast Care - November 13, 2018 Category: Cancer & Oncology Source Type: research

Relationship between Ribosomal Protein S6-pS240 Expression and other Prognostic Factors in Non-Special Type Invasive Breast Cancer
Background: The aim of this study was to investigate the immunohistochemical expression of ribosomal protein (RP) S6-pS240 in non-special type invasive breast cancer in relation to other prognostic markers and gain new insights to facilitate more individualized treatment.Methods: The following clinical and histopathological parameters of 120 patients were determined: S6-pS240 expression, age, menopausal status, tumor size and grade, TNM stage, Nottingham Prognostic Index (NPI), lymph node stage, estrogen and progesterone receptor (ER/PR) expression, HER2/neu amplification, lymphovascular invasion, and proliferative index a...
Source: Breast Care - November 13, 2018 Category: Cancer & Oncology Source Type: research

Autologous Lipotransfer - Daily Therapeutic Practice in Breast Cancer: An Intergroup Analysis Encompassing NOGGO, WSG, GBG, AWO Gyn and DGPR ÄC
Conclusions: The lack of randomized controlled data, especially in high-risk patients, demonstrates the necessity for a registry study on this topic. Our survey describes, in detail, the indications for lipofilling as well as its appropriate application in breast cancer patients in Germany and may thereby reduce the present therapeutic uncertainties.Breast Care (Source: Breast Care)
Source: Breast Care - November 13, 2018 Category: Cancer & Oncology Source Type: research

Re-Excision Rates in Breast-Conserving Surgery for Invasive Breast Cancer after Neoadjuvant Chemotherapy with and without the Use of a Radiopaque Tissue Transfer and X-ray System
Conclusion: Our analysis provides a rationale for the routine use of a radiopaque tissue transfer system for specimen radiography in BCS after neoadjuvant chemotherapy for invasive breast cancer in order to reduce re-excision rates.Breast Care (Source: Breast Care)
Source: Breast Care - November 13, 2018 Category: Cancer & Oncology Source Type: research

Gynecomastia - Conservative and Surgical Management
Gynecomastia is defined as a unilateral or bilateral persistent benign mammary gland enlargement in men. Prevalence of asymptomatic gynecomastia is up to 65%. True gynecomastia must be distinguished from pseudogynecomastia. Typically, in true gynecomastia, a solid tissue mass is palpable below the nipple-areolar complex. Malignant changes such as male mammary carcinoma must always be ruled out. The causes of gynecomastia are diverse. An imbalance of female to male hormones triggers the onset of the disease. This imbalance can be caused by endogenous diseases like hyperthyroidism, chronic liver disease, primary or secondary...
Source: Breast Care - November 13, 2018 Category: Cancer & Oncology Source Type: research